205 related articles for article (PubMed ID: 2248079)
21. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant.
Colzi A; d'Agostini F; Cesura AM; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S17-20. PubMed ID: 1546133
[TBL] [Abstract][Full Text] [Related]
22. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
23. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
[TBL] [Abstract][Full Text] [Related]
24. Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies.
Callingham BA
Br J Psychiatry Suppl; 1989 Oct; (6):53-60. PubMed ID: 2619973
[TBL] [Abstract][Full Text] [Related]
25. Moclobemide. An update of its pharmacological properties and therapeutic use.
Fulton B; Benfield P
Drugs; 1996 Sep; 52(3):450-74. PubMed ID: 8875133
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
27. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
[TBL] [Abstract][Full Text] [Related]
28. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
29. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.
Da Prada M; Zürcher G; Wüthrich I; Haefely WE
J Neural Transm Suppl; 1988; 26():31-56. PubMed ID: 3283290
[TBL] [Abstract][Full Text] [Related]
30. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.
Cesura AM; Kettler R; Imhof R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S15-6. PubMed ID: 1546132
[TBL] [Abstract][Full Text] [Related]
31. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
Gal S; Abassi ZA; Youdim MB
Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
33. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
Bieck PR
Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
[TBL] [Abstract][Full Text] [Related]
34. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
Bieck PR; Antonin KH
J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
[TBL] [Abstract][Full Text] [Related]
35. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.
Audebert C; Blin O; Monjanel-Mouterde S; Auquier P; Pedarriosse AM; Dingemanse J; Durand A; Cano JP
Eur J Clin Pharmacol; 1992; 43(5):507-12. PubMed ID: 1483487
[TBL] [Abstract][Full Text] [Related]
36. Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants.
Priest RG
Acta Psychiatr Scand Suppl; 1990; 360():39-41. PubMed ID: 2248065
[No Abstract] [Full Text] [Related]
37. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline.
Todd KG; Baker GB
J Affect Disord; 1995 Dec; 35(3):125-9. PubMed ID: 8749840
[TBL] [Abstract][Full Text] [Related]
38. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
Norman TR; Burrows GD
Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
Humphrey SJ; Curry JT; Turman CN; Stryd RP
J Cardiovasc Pharmacol; 2001 May; 37(5):548-63. PubMed ID: 11336106
[TBL] [Abstract][Full Text] [Related]
40. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers.
Berlin I; Zimmer R; Cournot A; Payan C; Pedarriosse AM; Puech AJ
Clin Pharmacol Ther; 1989 Sep; 46(3):344-51. PubMed ID: 2673623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]